美股异动 | 新药凯捷乐在中国获批上市 再鼎医药(ZLAB.US)涨超7%

Core Viewpoint - Zai Ding Pharmaceutical (ZLAB.US) shares rose over 7% to $18.84 following the approval of a new drug application for Nemonapride Chloride Capsules (Kai Jie Le) by the National Medical Products Administration of China, marking a significant breakthrough in the treatment of schizophrenia with a novel mechanism of action [1] Company Summary - Zai Ding Pharmaceutical's stock price increased by more than 7% to $18.84 as of the latest update [1] - The company's Hong Kong stock also saw a rise of 6.24% on the same day [1] - The newly approved drug is the first schizophrenia treatment with a new mechanism in over 70 years, representing a fundamental breakthrough in the field [1]